Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10393
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMalcontenti-Wilson, Caterinaen
dc.contributor.authorChan, Lisaen
dc.contributor.authorNikfarjam, Mehrdaden
dc.contributor.authorMuralidharan, Vijayaragavanen
dc.contributor.authorChristophi, Christopheren
dc.date.accessioned2015-05-15T23:49:48Z
dc.date.available2015-05-15T23:49:48Z
dc.date.issued2007-06-07en
dc.identifier.citationJournal of Gastroenterology and Hepatology 2007; 23(7 Pt 2): e96-e104en
dc.identifier.govdoc17559382en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10393en
dc.description.abstractOxi4503 is a potent vascular targeting agent belonging to the family of combretastatins. These agents produce an acute reduction in tumor blood flow leading to tumor necrosis. Despite evidence of its efficacy in certain malignancies, the effect on colorectal liver metastases remains largely unknown. This study investigates the effect of Oxi4503 on colorectal liver metastases in a murine model.The effect of a single dose of Oxi4503 on established tumors in a murine model of colorectal liver metastases was assessed following administration of 1-50 mg/kg Oxi4503. In addition, the effects of continuous, daily and intermittent dosing (1-5 mg/kg) on tumor necrosis and growth were studied by quantitative histological and stereological analysis. The effect of multiple dosing on long-term survival was also assessed using the Kaplan-Meier analysis. The microvascular effects of therapy were studied by scanning electron microscopy of microvascular resin casts.A single dose of 5 or 50 mg/kg of Oxi4503 produced significant tumor necrosis compared to the controls. Subcutaneous continuous dosing infusion with Oxi4503 at 1 mg/kg/day reduced tumor growth compared to the controls, but was associated with marked systemic toxicity. Daily administration over 21 days was associated with significant mortality. Intermittent dosing of Oxi4503 (two doses, 3 days apart) produced the greatest reduction in tumor growth with minimal toxicity and conferred a significant survival advantage. Microvascular casts demonstrated significant disruption of tumor vessels.A single dose of Oxi4503 produced significant necrosis and microvascular injury in colorectal liver metastases. Intermittent dosing with Oxi4503 produced the maximum reduction in tumor growth, minimal toxicity, and a significant improvement in survival. Oxi4503 is a potential anticancer agent. Further research into its mechanism of action and its synergistic use with other therapies is warranted.en
dc.language.isoenen
dc.subject.otherAnimalsen
dc.subject.otherAntineoplastic Agents.administration & dosage.pharmacology.toxicityen
dc.subject.otherCell Line, Tumoren
dc.subject.otherCell Proliferation.drug effectsen
dc.subject.otherColorectal Neoplasms.blood supply.drug therapy.pathologyen
dc.subject.otherDiphosphates.administration & dosage.pharmacology.toxicityen
dc.subject.otherDose-Response Relationship, Drugen
dc.subject.otherDrug Administration Scheduleen
dc.subject.otherInfusion Pumps, Implantableen
dc.subject.otherInfusions, Parenteralen
dc.subject.otherInjections, Intraperitonealen
dc.subject.otherLiver Neoplasms, Experimental.blood supply.drug therapy.secondaryen
dc.subject.otherMaleen
dc.subject.otherMiceen
dc.subject.otherMice, Inbred CBAen
dc.subject.otherMicrocirculation.drug effects.pathologyen
dc.subject.otherNecrosisen
dc.subject.otherRegional Blood Flow.drug effectsen
dc.subject.otherStilbenes.administration & dosage.pharmacology.toxicityen
dc.subject.otherTime Factorsen
dc.titleVascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Gastroenterology and Hepatologyen
dc.identifier.affiliationDepartment of Surgery, Austin Hospital, University of Melbourne, Melbourne, Victoria, Australiaen
dc.identifier.doi10.1111/j.1440-1746.2007.04899.xen
dc.description.pagese96-e104en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/17559382en
dc.type.austinJournal Articleen
local.name.researcherChristophi, Christopher
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptSurgery (University of Melbourne)-
crisitem.author.deptSurgery (University of Melbourne)-
crisitem.author.deptHepatopancreatobiliary Surgery-
crisitem.author.deptSurgery-
crisitem.author.deptSurgery-
crisitem.author.deptHepatopancreatobiliary Surgery-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

46
checked on Dec 26, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.